T h e serum-derived lipid growth factors, lysophosphatidate (LPA) and sphingosine 1 -phosphate (S1 P), activate cells selectively through different members of a family of endothelial differentiation gene (EDG) receptors. Activation of EDG receptors by LPA and S1P provides a variety of signalling cascades depending upon the G-protein coupling of the different EDG receptors. This leads to chemotactic and mitogenic responses, which are important in wound healing. For example, LPA stimulates fibroblast division and S1 P stimulates the chemotaxis and division of endothelial cells leading to angiogenesis. Counteracting these effects of LPA and S l P , are the actions of lipid phosphate phosphatases (LPP, or phosphatidate phosphohydrolases, Type 2). T h e isoform LPP-1 is expressed in the plasma membrane with its active site outside the cell. This enzyme is responsible for ' ecto-phosphatase ' activity leading to the degradation of exogenous lipid phosphate mediators, particularly LPA. Expression of LPP-1 decreases cell activation by exogenous LPA. T h e mechanism for this is controversial and several mechanisms have been proposed. Evidence will be presented that the LPPs cross-talk with EDG and other growth factor receptors, thus, regulating the responses of the cells to lipid phosphate mediators of signal transduction.
Introduction
Lipid phosphate esters, including lysophosphatidate (LPA), phosphatidate (PA), sphingosine 
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1-phosphate (SIP) and, possibly, ceramide 1 -phosphate (C1 P), are bioactive lipids and control cell activation (Figures 1 and 2 ). There are two modes in which this can operate. T h e bioactive lipid phosphates can be present outside the cell and signal through a series of cell surface receptors, or the lipid mediators can control cell activation intracellularly (for review see [ 11) .
Extracellular signalling
LPA is produced by activated platelets [2] and by injured tissue, including corneal tissue [3]. Serumderived LPA serves as a growth factor for stimulating tissue repair. LPA can also be produced by adipocytes when they are activated with a,-adrenergic agonists [4] . This LPA may be a regulator of pre-adipocyte growth. LPA can also be produced in inflammatory conditions by the action of secretory phospholipase A, [S] . In addition, LPA can be secreted by ovarian cancer cells to promote the development of the tumour [6, 7] and protects it against apoptosis initiated by chemotherapeutic agents [8] . These latter observations suggest that the paracrine effects of LPA contribute to the poor prognosis associated with chemotherapy for ovarian cancer. LPA concentrations are also raised in the blood of patients with multiple myeloma [9] . Therefore, the growth factor effects of LPA are of considerable biological and clinical importance. S1 P is also secreted by activated platelets [lo] and ovarian cancer cells [ l l ] . One of the major effects of S1 P is to stimulate the formation of new blood vessels (angiogenesis) ([12,13] , and for review see [14] ). In fact, S1P accounts for about 80 "6 of chemotactic activity towards endothelial cells leading to their proliferation and the formation of new blood vessels [ 151. Angiogenesis is an important aspect of wound repair and it is also necessary for the growth of aggressive tumours.
S I P and LPA stimulate cells through a series of endothelial differentiation gene (EDG) receptors. EDG-1, -3, -5, -6 and -8 bind S I P selectively, whereas EDG-2, -4, and -7 are specific for LPA . These E D G receptors are coupled through heterotrimeric G-proteins (Figure 3 ).
PA can be derived from phosphatidylcholine afteragonist stimulation of PLD I or PLDZ. In terms of vesicle traficking. PLD I is particularly important and it is activated by ARF. PA is also produced from LPA by acyttransferases, including endophilin and BARS-50. Both of these acyttransferases are involved in vesicle movement. PA can also be produced from DAG by a family of DAG kinases. PA can be converted t o LPA, which is an important extracellular growth factor acting through EDG receptors. The role of PAP-I or LPPs in dephosphorylating PA or LPA is also illustrated. 
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Formation of bioactive sphingolipids and the role of LPPs
Cytokines such as tumour necrosis factor a. interleukin-I or y-interferon stimulate sphingomyelinases, which leads t o the formation of ceramides These latter lipids can either be phosphorylated t o C I P. or be converted by ceramidases to sphingosine and then t o S I P by sphingosine kinases Sphingosine kinase activity can also be stimulated by activation of the platelet-denved growth factor receptor or, in some cells, by tumour necrosis factor a The role of the LPPs or mSPP-I in dephosphorylating C I P or S I P is also emphasized [25, 26] . This formation of PA may be produced through the activation of P L D l , an enzyme that is stimulated by the G-protein, ADP ribosylation factor (ARF). P L D l and ARF are known to be involved in vesicle movement [27] . In addition, PA may be formed through the actions of endophilin, which is responsible for the acylation of LPA (Figure 1) . It is therefore postulated that endophilin (with dynamin) may mediate synaptic vesicle endocytosis from the plasma membrane, via PA formation [28] . Likewise, in Golgi membranes, LPA can be acylated by brefeldin A-ADP-ribosylated substrate 50 kDa (BARS-50) to form PA [29] . This activity is necessary for the fusion machinery involved in the formation of COP-1 -coated vesicles.
T h e turnover of PA depends largely upon its metabolism by phosphatases to diacylglycerol, or its de-acylation by phospholipase-A, or -A, yielding LPA (Figure 1 ).
Phosphatidate phosphohydrolases and lipid phosphate phosphatases
Two different types of phosphatidate phosphohydrolase (PAP-1 and PAP-2) can dephosphorylate lipids such as PA. PAP-1 was first identified as an enzyme in the Kennedy pathway where it provides DAG for the synthesis of triacylglycerol, phosphatidylcholine and phosphatidylethanolamine (for review a see [30] ). PAP-1 has an absolute requirement for Mg'+ and it is inhibited strongly by N-ethylmaleimide. PAP-1 is located mainly in the cytosol of cells and serves as an inactive reservoir of activity. I t is translocated onto membranes to become active in glycerolipid synthesis when fatty acids accumulate. T h e active site of PAP-1 is assumed to be on the cytosolic surface of membranes such as the endoplasmic reticulum.
Theoretically, PAP-1 could be involved in signal transduction by changing the relative ratio of PA to DAG (Figure l ) , although there is limited evidence to support this hypothesis. However, it has been shown that PAP-1 participates in cyclooxygenase expression and eicosanoid formation after protein kinase C activation of WISH cells (an amnion cell line) [31] . A further argument that PAP-1 participates in cell signalling is provided by the observation that PAP-1 activity co-immunoprecipitates with activated epidermal growth factor receptors [32] . Thus far, no group has been able to purify PAP-1 to homogeneity and there is no indication of the structure of this enzyme. As a result, there is relatively little new work advancing the understanding of the role of PAP-1 in signal transduction or glycerolipid synthesis.
PAP-2 is characterized by its lack of inhibition by N-ethylmaleimide and by not having a requirement for bivalent cations (e.g. Mg") [1, 33] . PAP-2 has a broad substrate specificity in that it dephosphorylates PA, LPA, S1 P, C l P and diacylglycerol pyrophosphate. Consequently, it was proposed that PAP-2 could modulate signal transduction by changing the balance of the phosphorylated lipid mediators relative to their dephosphorylated counterparts [ 11. In many instances, these products are also bioactive, e.g. DAG, ceramide and sphingosine (Figures 1 and  2 ). I t was proposed that the names of the PAP-2 enzymes should be changed to lipid phosphate phosphatases (LPPs) to reflect the substrate specificities of these enzymes and the present uncertainty as to which lipids are physiologically relevant substrates [33] .
Investigations on the role of the LPPs were aided greatly by the cloning of the DNA for LPP-1 by Kai et al. [34] . Subsequently, other groups also contributed to the cloning of different LPP isoforms (see [1, 33] for reviews). We now know that there are at least four different isoforms. LPP-1 is equivalent to PAP-2a; LPP-2 is equivalent to PAP-2c; LPP-3 is equivalent to PAP-2b and rat Dri42. These isoforms appear to have relatively broad substrate specificity. However, another member of the LPP family, mammalian sphingosine 1 -phosphate phosphatase (mSPP-I), has been identified by Mandala et al. [35] . This enzyme is specific for S1 P (Figure 2 ).
T h e family of LPPs is characterized by having three conserved domains that identify the LPPs as belonging to a phosphatase superfamily [36] . This family also includes bacterial and yeast phosphatases, fungal chloroperoxidase and mammalian glucose 6-phosphatase (see [1, 33] 
for reviews).
Mutational studies demonstrated that the conserved residues were, indeed, required for mammalian LPP-1 activity [37] . LPP-1, LPP-2 and LPP-3 have six proposed transmembrane domains. These enzymes are partly expressed on the plasma membrane of cells. T h e C-and N-termini of LPP-1 were shown to be located on the cytosolic surface of membranes. This implies that the active site of these enzymes, which is constituted by the three conserved domains, lies on the outside of the cell [37] , or on the luminal surface of the endoplasmic reticulum or Golgi. This topology implies that the LPPs can act as ' ecto-enzymes ' and dephosphorylate exogenous lipid phosphate esters without the need for the substrates to be transported across the plasma membrane. Overexpression of LPP-1, LPP-2 and LPP-3 increases the degradation of exogenous lipid phosphates [38, [40] [41] [42] [43] [44] .
It was, therefore, proposed that the LPPs would attenuate signalling by exogenous LPA since the product of the reaction is monoacylglycerol, which should not be bioactive [38] . In the case of PA, the LPPs produce DAG, which is taken up by cells. Thus, the ecto-LPP activity can increase cell activation by intracellular DAG, or by intracellular PA after the action of DAG kinase [41] . Likewise, exogenous S1P is converted to sphingosine, which can also enter cells where it is converted to the bioactive compounds, ceramide or SIP.
T h e mechanisms whereby the LPPs regulate cell signalling by exogenous lipid phosphates are, at present, controversial. It is generally accepted that the LPPs can act as ectoenzymes [38, [40] [41] [42] [43] [44] , thereby implying that they participate in regulating the steady-state concentration of S1 P and LPA in biological fluids. This in turn would implicate the LPPs as regulators of E D G receptor activation. However, the effect of overexpressing LPP-1 on cell signalling was observed under conditions where only a small proportion of the exogenous LPA was degraded. This implies that the role of the LPPs may be more complicated than simply degrading exogenous substrates [38] . T h e discrepancy could be explained if there were to be a specific pool of LPA that was responsible for E D G receptor activation which could be regulated selectively by the LPPs. For example, this pool could result from the binding of LPA to the surface membrane of cells where LPA could then interact competitively with E D G receptors or the LPPs [42] . T h e main problem with this latter work is that the amount of LPA that interacts with cells is very small and measuring specific binding accurately is extremely difficult.
Work by Hooks et al.
[43] provided another interpretation. These authors employed nonhydrolyzable analogues of LPA to study the mitogenic effects of LPA and structural analogues and their actions on platelet aggregation. They concluded that the ligand selectivity for platelet aggregation was similar to that for mitogenesis, but this did not correlate with the ability of the compounds to activate EDG-2, EDG-4 and EDG-7. It was concluded that LPA-induced mitogenesis is regulated by LPPs, but in some cells is not mediated by the known E D G receptors for LPA.
Alderton et al. [44] showed that cells transfected with LPP-1, LPP-la and LPP-2, but not with LPP-3, showed diminished activation of ERK by LPA, S1P and PA. These effects appear to be correlated with decreased intracellular concentrations of PA, but not with the ecto-LPP activity. This conclusion was supported by the observation that overexpression of LPP-1, LPPl a and LPP-2 attenuated the activation of MAP kinase by thrombin. This latter agonist signals via a G-protein-coupled receptor that does not depend upon LPA availability. It was, therefore, proposed that LPP-1, LPP-la and LPP-2 might modulate cell signalling downstream of some Gprotein-coupled receptors, rather than limiting the availability of bioactive lipid agonists at their respective receptors. Previous work has already shown that overexpression of LPP-1 lowered the concentration of PA in cells [45] , although this result was not confirmed by Roberts and Morris T h e structure of mSPP-1 appears to be different to that of the LPPs. In addition to six transmembrane regions around the active site, there appear to be three or four additional hydrophobic regions towards the C-terminus, in contrast with LPP-1. T h e only potential glycosylation site is predicted to be on the side of the membrane opposite to the active site [46] . By contrast with the LPPs, mSPP-1 is inhibited by detergents such as Triton X-100 and it is not inhibited by amphiphilic cations such as propanolol. mSPP-1 is probably the mammalian orthologue of yeast LBPl.
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Expression of the mSPP-1 in NIH-3T3 fibroblasts decreased intracellular concentration of S1 P and increased ceramide concentrations [35] . It also diminished the survival of cells and induced the characteristic traits of apoptosis. These results support the hypothesis that members of the LPP family change the balance between different lipid second messengers and, thus, influence signal transduction. This work implicates mSPP-1 in regulating intracellular signalling by S1 P.
It has been proposed that S1P is secreted and acts in an autocrine/paracrine mode that results in the activation of cell surface E D G receptors [47] . T h e ecto-activity of the LPPs could diminish the availability of exogenous S1 P to stimulate surface receptors. T h e autocrine/paracrine role for S1 P provides an attractive mechanism for the regulation of cell signalling. T h e main problem with this concept is that significant quantities of extracellular SIP are normally not detected when sphingosine kinase is activated [47] , even when the ecto-activity of the LPPs is inhibited (C. Pilquil and D. N. Brindley, unpublished work). Furthermore, the mechanism for the secretion of SIP, which is a polar lipid, from most cells has not been elucidated.
Conclusions
Recent work has established the important functions of the LPPs in attenuating cell signalling by both intra-and extra-cellular lipid phosphates such as LPA, PA and S1P. T h e LPPs also produce other potentially bioactive lipids such as DAG, ceramide and sphingosine, thus further modifying the direction and balance of signal transduction. At present, the biological substrate preferences of the different LPPs, as opposed to their abilities to dephosphorylate different lipids in detergent micelles in vitro, is not well established. T h e physiological actions of the LPPs could be modified in cells by the abilities of different substrates to access the various LPP isoforms. Furthermore, the differential functions of splice variants of the LPPs [1, 33] are not understood. Finally, the exact mechanisms for how the LPPs attenuate cell activation by the exogenous lipid phosphates and other agonists needs to be resolved. These aspects should provide fruitful areas of research since LPA, PA and S1P are potent mediators of signal transduction in a large variety of medically important areas. 
